FDA Approves Moderna's mRNA Influenza Vaccine
核心洞察
The US FDA has approved Moderna's mRNA-based seasonal influenza (搜索) vaccine mFlusiva (搜索) for people aged 50 to 64, the first flu vaccine using mRNA production.
mFlusiva (搜索) encodes full-length viral hemagglutinin (搜索) surface glycoproteins from three WHO-recommended influenza (搜索) strains, delivered by lipid nanoparticles into cells.
In two clinical trials, mFlusiva (搜索) outperformed GlaxoSmithKline's four-strain Fluarix in preventing influenza (搜索) infection or eliciting antibody responses.
The US Food and Drug Administration has approved Moderna's mRNA flu vaccine for people aged 50–64. mFlusiva (搜索) is the first seasonal influenza (搜索) vaccine to use mRNA-based production, an approach that allows vaccines to be quickly updated to match circulating influenza strains and could result in improved protection.
The vaccine carries mRNA encoding full-length viral hemagglutinin (搜索) surface glycoproteins from three World Health Organization (WHO)-recommended influenza (搜索) strains, packaged in lipid nanoparticles that deliver the payload into cells. Cells translate the mRNA into hemagglutinin proteins that are recognized by the immune system, stimulating immune responses that protect against influenza.
In two clinical trials, mFlusiva (搜索) out-performed an existing flu vaccine, GlaxoSmithKline's four-strain influenza (搜索) vaccine Fluarix, in preventing influenza infection or eliciting antibody responses.